Chris Raggio approaches the world as an engineer: identify a need, then build a solution. He carried this mindset through medical school, earning his MD before training in psychiatry, only to discover that modern medicine relies too heavily on accident and trial-and-error rather than deliberate design.
Convinced that biology must be engineered with intention, Chris shifted toward investing in contrarian science and technology through his family office, including early bets on Bitcoin and synthetic biology. He ultimately acquired Avery Bio, becoming an active presence in the SynBioBeta community.
Conversations with Drew Endy and Kate Adamala's research on synthetic cells crystallized his vision. He co-founded Biotic to build open infrastructure for synthetic cell engineering: a quiet steward championing foundational science he believes will transform medicine from accident into intention.